1. |
Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B:special emphasis on disease progression and prognostic factors. J Hepatol, 2008, 48(2):335-352.
|
2. |
Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol, 2013, 28 Suppl 1:7-10.
|
3. |
Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2):74-108.
|
4. |
Nuzzo G, Giuliante F, Ardito F, et al. Intrahepatic cholangiocarci-noma:prognostic factors after liver resection. Updates Surg, 2010, 62(1):11-19.
|
5. |
Cho SY, Park SJ, Kim SH, et al. Survival analysis of intrahepatic cholangiocarcinoma after resection. Ann Surg Oncol, 2010, 17(7):1823-1830.
|
6. |
Murakami Y, Uemura K, Sudo T, et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol, 2011, 18(3):651-658.
|
7. |
Shimada K, Sano T, Sakamoto Y, et al. Surgical outcomes of the mass-forming plus periductal infiltrating types of intrahepatic cholangiocarcinoma:a comparative study with the typical mass-forming type of intrahepatic cholangiocarcinoma. World J Surg, 2007, 31(10):2016-2022.
|
8. |
Nakagohri T, Kinoshita T, Konishi M, et al. Surgical outcome and prognostic factors in intrahepatic cholangiocarcinoma. World J Surg, 2008, 32(12):2675-2680.
|
9. |
Hashimoto K, Miller CM. Liver transplantation for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci, 2015, 22(2):138-143.
|
10. |
Maganty K, Levi D, Moon J, et al. Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma:outcome after liver transplantation. Dig Dis Sci, 2010, 55(12):3597-3601.
|
11. |
Sapisochin G, de Lope CR, Gastaca M, et al. Intrahepatic cholangio-carcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation:a Spanish matched cohort multi-center study. Ann Surg, 2014, 259(5):944-952.
|
12. |
Yoon YI, Hwang S, Lee YJ, et al. Postresection outcomes of combined hepatocellular carcinoma-cholangiocarcinoma, hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Gastrointest Surg, 2016, 20(2):411-420.
|
13. |
Lee CS, Friedman JR, Fulmer JT, et al. The initiation of liver development is dependent on Foxa transcription factors. Nature, 2005, 435(744):944-947.
|
14. |
Li Z, Gadue P, Chen K, et al. Foxa2 and H2A.Z mediate nucleosome depletion during embryonic stem cell differentiation. Cell, 2012, 151(7):1608-1616.
|
15. |
Pristerà A, Lin W, Kaufmann AK, et al. Transcription factors FOXA1 and FOXA2 maintain dopaminergic neuronal properties and control feeding behavior in adult mice. Proc Natl Acad Sci U S A, 2015, 112(35):E4929-E4938.
|
16. |
Wang J, Zhu CP, Hu PF, et al. FOXA2 suppresses the metastasis of hepatocellular carcinoma partially through matrix metalloprotei-nase-9 inhibition. Carcinogenesis, 2014, 35(11):2576-2583.
|
17. |
Perez-Balaguer A, Ortiz-Martínez F, García-Martínez A, et al. FOXA2 mRNA expression is associated with relapse in patients with Triple-Negative/Basal-like breast carcinoma. Breast Cancer Res Treat, 2015, 153(2):465-474.
|
18. |
Jang SM, An JH, Kim CH, et al. Transcription factor FOXA2-centered transcriptional regulation network in non-small cell lung cancer. Biochem Biophys Res Commun, 2015, 463(4):961-967.
|
19. |
Vorvis C, Hatziapostolou M, Mahurkar-Joshi S, et al. Transcriptomic and CRISPR/Cas9 technologies reveal FOXA2 as a tumor suppressor gene in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol, 2016, 310(11):G1124-G1137.
|
20. |
Tang Y, Shu G, Yuan X, et al. FOXA2 functions as a suppressor of tumor metastasis by inhibition of epithelial-to-mesenchymal transition in human lung cancers. Cell Res, 2011, 21(2):316-326.
|
21. |
Zhang Z, Yang C, Gao W, et al. FOXA2 attenuates the epithelial to mesenchymal transition by regulating the transcription of E-cadherin and ZEB2 in human breast cancer. Cancer Lett, 2015, 361(1):240-250.
|
22. |
Song Y, Washington MK, Crawford HC. Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res, 2010, 70(5):2115-2125.
|
23. |
张正良, 孙江利, 白郑海, 等. FOXA2在胃腺癌中的表达降低.细胞与分子免疫学杂志, 2015, 31(5):672-676.
|
24. |
Yoo T, Park SJ, Han SS, et al. Postoperative CA19-9 change is a useful predictor of intrahepatic cholangiocarcinoma survival following liver resection. Dis Markers, 2015, 2015:298985.
|
25. |
Sulpice L, Rayar M, Boucher E, et al. Treatment of recurrent intrahepatic cholangiocarcinoma. Br J Surg, 2012, 99(12):1711-1717.
|
26. |
Kondratyeva LG, Sveshnikova AA, Grankina EV, et al. Downregulation of expression of mater genes SOX9, FOXA2, and GATA4 in pancreatic cancer cells stimulated with TGF beta 1 epithelial-mesen-chymal transition. Dokl Biochem Biophys, 2016, 469(1):257-259.
|
27. |
Smith B, Neff R, Cohn DE, et al. The mutational spectrum of FOXA2 in endometrioid endometrial cancer points to a tumor suppressor role. Gynecol Oncol, 2016, 143(2):398-405.
|